Polyneuron Pharmaceuticals AG
Polyneuron Pharmaceuticals develops a novel class of biodegradable glycopolymers using its Antibody-Catch technology platform to treat antibody-mediated autoimmune diseases. These injectable drugs act as decoys to selectively sequester and eliminate pathological autoantibodies while leaving the rest of the immune system intact. The company's lead candidate, PN-1007, targets anti-MAG neuropathy, a chronic disorder of the peripheral nervous system.
Biotechnology
Pharmaceuticals
Healthtech
Funding summary
- Total raised
- €33.0M
- Funding rounds
- 2
Investors in Polyneuron Pharmaceuticals AG
Investors on record for Polyneuron Pharmaceuticals AG. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Polyneuron Pharmaceuticals AG?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors